I’m referring to 10 years from now when the Recell patent expires. Right now, Avita would sue and win a patent lawsuit if anyone tried to copy with a generic version. After the patent expires, newcomers can compete, but they still must prove themselves with expensive and time-consuming clinical trials. Why? —Because there’s no guarantee that their generic product would be effective without clinical trials. We’re not talking about pharmaceuticals here; this is a device with several different mechanisms that may prove difficult to emulate.
- Forums
- ASX - By Stock
- Patent extension
I’m referring to 10 years from now when the Recell patent...
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVH (ASX) to my watchlist
|
|||||
Last
$2.77 |
Change
0.100(3.75%) |
Mkt cap ! $195.7M |
Open | High | Low | Value | Volume |
$2.77 | $2.82 | $2.74 | $920.7K | 331.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 883 | $2.77 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.78 | 2072 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2000 | 2.780 |
4 | 3667 | 2.770 |
3 | 3350 | 2.760 |
5 | 5303 | 2.750 |
4 | 17988 | 2.740 |
Price($) | Vol. | No. |
---|---|---|
2.790 | 2067 | 5 |
2.800 | 16111 | 6 |
2.810 | 23660 | 5 |
2.820 | 9316 | 3 |
2.840 | 10000 | 1 |
Last trade - 15.48pm 11/09/2024 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |